1041559-56-1

Basic information

• Product Name: 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid
• Synonyms: 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid
• CAS NO: 1041559-56-1
• Molecular Weight: 301.339
• Mol File: 1041559-56-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid(1041559-56-1)
• EPA Substance Registry System: 5-(N-cyclohexylsulfamoyl)-2-fluorobenzoic acid(1041559-56-1)

Safety Data

• Hazardous Substances Data: 1041559-56-1(Hazardous Substances Data)

Upstream product

• 108-91-8 cyclohexylamine 
• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 

Downstream Products

• 1417714-71-6 C₁₃H₁₅ClFNO₃S 
• 1572509-70-6 5-(cyclohexylsulfamoyl)-2-fluoro-N-phenylbenzamide 
• 1574311-46-8 C₁₉H₂₀F₂N₂O₂S₂ 
• 1572509-68-2 5-(cyclohexylsulfamoyl)-2-fluoro-N-(4-fluorophenyl)benzamide 
• 422553-31-9 C₂₀H₂₀F₄N₂O₃S 

Relevant articles and documents

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)

Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.

FUSED BICYCLIC SULFAMOYL DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein A-E, R1, R2, R3 and R5, have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.